BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 252 filers reported holding BIO-TECHNE CORP in Q1 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $8,419,238 | -12.1% | 123,685 | +5.4% | 0.01% | -9.1% |
Q2 2023 | $9,578,791 | +89.8% | 117,344 | +72.5% | 0.01% | +83.3% |
Q1 2023 | $5,046,552 | -31.1% | 68,022 | -23.0% | 0.01% | -33.3% |
Q4 2022 | $7,320,625 | +9.9% | 88,328 | +278.8% | 0.01% | +12.5% |
Q3 2022 | $6,661,000 | -5.3% | 23,320 | +14.9% | 0.01% | 0.0% |
Q2 2022 | $7,035,000 | -28.2% | 20,296 | -10.3% | 0.01% | -11.1% |
Q1 2022 | $9,800,000 | -24.1% | 22,631 | -9.3% | 0.01% | -18.2% |
Q4 2021 | $12,915,000 | +8.1% | 24,965 | +1.3% | 0.01% | -8.3% |
Q3 2021 | $11,946,000 | +57.0% | 24,652 | +56.2% | 0.01% | +50.0% |
Q2 2021 | $7,610,000 | +99.5% | 15,781 | +58.0% | 0.01% | +100.0% |
Q1 2021 | $3,815,000 | +20.1% | 9,990 | -0.1% | 0.00% | 0.0% |
Q4 2020 | $3,176,000 | +47.4% | 10,000 | +14.9% | 0.00% | +33.3% |
Q3 2020 | $2,155,000 | +70.0% | 8,700 | +81.2% | 0.00% | +50.0% |
Q2 2020 | $1,268,000 | -21.1% | 4,800 | -69.3% | 0.00% | -33.3% |
Q4 2016 | $1,608,000 | -38.4% | 15,635 | -34.4% | 0.00% | -40.0% |
Q3 2016 | $2,610,000 | +14.9% | 23,835 | +18.4% | 0.01% | +25.0% |
Q2 2016 | $2,271,000 | -22.8% | 20,135 | -35.3% | 0.00% | -20.0% |
Q1 2016 | $2,940,000 | +11.5% | 31,100 | +6.1% | 0.01% | 0.0% |
Q4 2015 | $2,637,000 | +295.9% | 29,300 | +306.9% | 0.01% | +400.0% |
Q3 2015 | $666,000 | -44.1% | 7,200 | -40.5% | 0.00% | -50.0% |
Q2 2015 | $1,191,000 | +46.7% | 12,100 | +49.4% | 0.00% | +100.0% |
Q1 2015 | $812,000 | +104.5% | 8,100 | +88.4% | 0.00% | 0.0% |
Q4 2014 | $397,000 | – | 4,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |